Status:
COMPLETED
Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression
Lead Sponsor:
Harvard Medical School (HMS and HSDM)
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Depression
Eligibility:
All Genders
19-64 years
Phase:
PHASE4
Brief Summary
This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).
Detailed Description
MDD is a serious mental illness that can interfere with a person's ability to eat, sleep, work, and enjoy activities that were once pleasurable. It is characterized by several symptoms, including as t...
Eligibility Criteria
Inclusion
- Clinical diagnosis of MDD (as defined by SCID \[DSM III-R\] and a score of at least 15 on the 21-item Hamilton Depression Scale)
- Able to swallow tablets, give urine and blood samples, and participate in periodic evaluations during the study
- Healthy volunteers show no current Axis I or Axis II disorders and score less than 8 on the Hamilton Depression Scale
Exclusion
- Use of any of the following medications within the 2 weeks prior to study entry: psychoactive medication; aspirin; or nonsteroidal anti-inflammatory agents
- Any alcohol or drug abuse within the 6 months prior to study entry
- Any major medical disorder
Key Trial Info
Start Date :
August 1 1990
Trial Type :
INTERVENTIONAL
End Date :
July 1 1993
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00320632
Start Date
August 1 1990
End Date
July 1 1993
Last Update
August 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts Mental Health Center
Boston, Massachusetts, United States, 02115